2025 capped a wave of advances for in vivo genetic medicines, and new experimental platforms extended that momentum into infectious‑disease and neurological arenas. The field review noted improving delivery technologies and clinical proof points for direct-in-body editing. Separately, researchers reported a bioengineered viral system that edits RNA in macrophages in vivo to treat sepsis—work published in Nature Communications that demonstrates cell‑type targeted RNA modification in living animals.